Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034619 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
A Phase 2 study of Colorectal Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00034619 is a Phase 2 study of Colorectal Cancer that has completed, run by Eli Lilly and Company. The trial reports 20 study locations across 11 states.
The verdict
NCT00034619, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG ALIMTA
Study Locations (20)
North Carolina
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Asheville
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Goldsboro
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Hendersonville
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Winston-Salem
Utah
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Ivins
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Ogden
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Provo
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - St. George
Pennsylvania
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Philadelphia
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Pittsburgh
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Reading
Oregon
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Bend
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Portland
Alabama
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Huntsville
Massachusetts
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Pittsfield
Michigan
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Kalamazoo
New York
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" - Latham
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034619
The ClinicalTrials.gov registry entry for NCT00034619 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT00034619 reports 20 study locations spanning 11 distinct geographic areas - top geographies include North Carolina, Utah, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00034619 about?
NCT00034619 is a clinical study titled "A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.". The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
What is the current status of trial NCT00034619?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00034619 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT00034619?
The interventions under investigation include: Oxaliplatin (DRUG), ALIMTA (DRUG).
Who is sponsoring clinical trial NCT00034619?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00034619 being conducted?
This trial has 20 study locations across Alabama, Massachusetts, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.